Ketazolam

	WikiDoc Resources for Ketazolam
Articles
Most recent articles on Ketazolam Most cited articles on Ketazolam Review articles on Ketazolam Articles on Ketazolam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ketazolam Images of Ketazolam Photos of Ketazolam Podcasts & MP3s on Ketazolam Videos on Ketazolam
Evidence Based Medicine
Cochrane Collaboration on Ketazolam Bandolier on Ketazolam TRIP on Ketazolam
Clinical Trials
Ongoing Trials on Ketazolam at Clinical Trials.gov Trial results on Ketazolam Clinical Trials on Ketazolam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ketazolam NICE Guidance on Ketazolam NHS PRODIGY Guidance FDA on Ketazolam CDC on Ketazolam
Books
Books on Ketazolam
News
Ketazolam in the news Be alerted to news on Ketazolam News trends on Ketazolam
Commentary
Blogs on Ketazolam
Definitions
Definitions of Ketazolam
Patient Resources / Community
Patient resources on Ketazolam Discussion groups on Ketazolam Patient Handouts on Ketazolam Directions to Hospitals Treating Ketazolam Risk calculators and risk factors for Ketazolam
Healthcare Provider Resources
Symptoms of Ketazolam Causes & Risk Factors for Ketazolam Diagnostic studies for Ketazolam Treatment of Ketazolam
Continuing Medical Education (CME)
CME Programs on Ketazolam
International
Ketazolam en Espanol Ketazolam en Francais
Business
Ketazolam in the Marketplace Patents on Ketazolam
Experimental / Informatics
List of terms related to Ketazolam

Ketazolam
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N05BA10 (WHO) ;
Legal status
Legal status	Schedule IV(US);
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Elimination half-life	26-200 hours
Excretion	Renal
Identifiers
	IUPAC name 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione;
CAS Number	27223-35-4 ;
PubChem CID	33746;
DrugBank	DB01587 ;
ChemSpider	31110 ;
UNII	92A214MD7Y;
KEGG	D04650 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C20H17ClN2O3
Molar mass	368.8
3D model (JSmol)	Interactive image;
	SMILES ClC1=CC2=C(N(C)C(CN3C(C=C(C)OC32C4=CC=CC=C4)=O)=O)C=C1;
	InChI InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3 ; Key:PWAJCNITSBZRBL-UHFFFAOYSA-N ;
(verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ketazolam (marketed under the brand names Anseren, Ansieten, Ansietil, Marcen, Sedatival, Sedotime, Solatran and Unakalm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

Therapeutic uses

It is used for the treatment of anxiety and has similar effectiveness compared to diazepam. Ketazolam also appears to produce a reduced level of side effects such as sedation compared with diazepam and the side effects when they occur tend to be milder.^[2]^[3]^[4]^[5] Ketazolam is also an effective antispasmodic drug and is used for the treatment of spasticity.^[6]^[7]^[8]

Availability

Ketazolam is not approved for sale in Australia, United Kingdom or the United States.^[9] In South Africa, GlaxoSmithKline markets ketazolam under its Solatran brand name.^[10] In Canada, ketazolam is listed in schedule IV of the Controlled Drugs and Substances Act, along with other benzodiazepines.^[11]

Tolerance and physical dependence

Chronic use of ketazolam as with other benzodiazepines can lead to physical dependence and the appearance of the benzodiazepine withdrawal syndrome upon cessation of use or decrease in dose. Tolerance to ketazolam's therapeutic effects occurs over a period of 15 days.^[12]

Contraindications and special caution

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, alcohol or drug-dependent individuals and individuals with comorbid psychiatric disorders.^[13]

Pharmacokinetics

Ketazolam breaks down in the blood to diazepam which breaks down to demoxepam which breaks down to desmethyldiazepam.^[14]

Warnings

The U.S. Food and Drug Administration warns that in Spain, ketazolam marketed as Marcen may sometimes be mistakenly confused with Narcan.^[15]

Legal status

Ketazolam is a List 3 drug under the Betäubungsmittelgesetz, like almost all benzodiazepines in Germany. Ketazolam is a List II drugs of the Opium Law in the Netherlands. Ketazolam is a Schedule IV drug under the Controlled Substances Act in the US.^[16]

References

↑ Vega D; Fernández D; Echeverría G (July 2001). "Ketazolam". Acta Crystallogr C. 57 (Pt 7): 848–50. doi:10.1107/S0108270101006175. PMID 11443263.
↑ Anhalt HS; Young R; Roginsky M (November 1980). "Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing". The Journal of clinical psychiatry. 41 (11): 386–92. PMID 6108319.
↑ Kim KK; Sirman A; Trainor FS; Lee BY (1980). "Anxiolytic efficacy and safety of ketazolam compared with diazepam and placebo". Clin Ther. 3 (1): 9–14. PMID 6105920.
↑ Fabre LF Jr; Harris RT (1976). "Double-blind placebo-controlled efficacy study of ketazolam (U-28,774)". J Int Med Res. 4 (1): 50–4. PMID 16791.
↑ Rickels K; Csanalosi I; Greisman P; Mirman MJ; Morris RJ; Weise CC; Weiss G (October 1980). "Ketazolam and diazepam in anxiety: a controlled study". J Clin Pharmacol. 20 (10): 581–9. doi:10.1002/j.1552-4604.1980.tb01673.x. PMID 6108335.
↑ Basmajian JV; Shankardass K; Russell D (August 1986). "Ketazolam once daily for spasticity: double-blind cross-over study". Arch Phys Med Rehabil. 67 (8): 556–7. PMID 2874780.
↑ Katz RT (June 1988). "Management of spasticity". Am J Phys Med Rehabil. 67 (3): 108–16. doi:10.1097/00002060-198806000-00004. PMID 3288246.
↑ Basmajian JV; Shankardass K; Russell D; Yucel V (November 1984). "Ketazolam treatment for spasticity: double-blind study of a new drug". Arch Phys Med Rehabil. 65 (11): 698–701. PMID 6149738.
↑ "Benzodiazepine Names". The Tranquilliser Recovery and Awareness Place. Retrieved 26 August 2008.
↑ "SOLATRAN 15 (capsules) - SOLATRAN 30 (capsules)". South African Electronic Package Inserts. 12 November 1985. Retrieved 26 August 2008.
↑ http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html#h-29
↑ Higgitt A; Fonagy P; Lader M (1988). "The natural history of tolerance to the benzodiazepines". Psychol Med Monogr Suppl. 13: 1–55. doi:10.1017/S0264180100000412. PMID 2908516.
↑ Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr. 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
↑ Joyce JR, Bal TS, Ardrey RE, Stevens HM, Moffat AC (June 1984). "The decomposition of benzodiazepines during analysis by capillary gas chromatography/mass spectrometry". Biomed Mass Spectrom. 11 (6): 284–9. doi:10.1002/bms.1200110607. PMID 6743768.
↑ Food and Drug Administration (January 2006). "FDA Public Health Advisory - Consumers Filling U.S. Prescriptions Abroad May Get the Wrong Active Ingredient Because of Confusing Drug Names". FDA (USA). Archived from the original on 12 August 2006. Retrieved 26 August 2006.
↑ Drug Enforcement Administration (USA). "Drug Scheduling". United States Government. Retrieved 26 August 2008.

Template:Benzodiazepines Template:Anxiolytics

[1] Vega D; Fernández D; Echeverría G (July 2001). "Ketazolam". Acta Crystallogr C. 57 (Pt 7): 848–50. doi:10.1107/S0108270101006175. PMID 11443263.

[2] Anhalt HS; Young R; Roginsky M (November 1980). "Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing". The Journal of clinical psychiatry. 41 (11): 386–92. PMID 6108319.

[3] Kim KK; Sirman A; Trainor FS; Lee BY (1980). "Anxiolytic efficacy and safety of ketazolam compared with diazepam and placebo". Clin Ther. 3 (1): 9–14. PMID 6105920.

[4] Fabre LF Jr; Harris RT (1976). "Double-blind placebo-controlled efficacy study of ketazolam (U-28,774)". J Int Med Res. 4 (1): 50–4. PMID 16791.

[5] Rickels K; Csanalosi I; Greisman P; Mirman MJ; Morris RJ; Weise CC; Weiss G (October 1980). "Ketazolam and diazepam in anxiety: a controlled study". J Clin Pharmacol. 20 (10): 581–9. doi:10.1002/j.1552-4604.1980.tb01673.x. PMID 6108335.

[6] Basmajian JV; Shankardass K; Russell D (August 1986). "Ketazolam once daily for spasticity: double-blind cross-over study". Arch Phys Med Rehabil. 67 (8): 556–7. PMID 2874780.

[7] Katz RT (June 1988). "Management of spasticity". Am J Phys Med Rehabil. 67 (3): 108–16. doi:10.1097/00002060-198806000-00004. PMID 3288246.

[8] Basmajian JV; Shankardass K; Russell D; Yucel V (November 1984). "Ketazolam treatment for spasticity: double-blind study of a new drug". Arch Phys Med Rehabil. 65 (11): 698–701. PMID 6149738.

[9] "Benzodiazepine Names". The Tranquilliser Recovery and Awareness Place. Retrieved 26 August 2008.

[10] "SOLATRAN 15 (capsules) - SOLATRAN 30 (capsules)". South African Electronic Package Inserts. 12 November 1985. Retrieved 26 August 2008.

[11] ttp://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-26.html#h-29

[12] Higgitt A; Fonagy P; Lader M (1988). "The natural history of tolerance to the benzodiazepines". Psychol Med Monogr Suppl. 13: 1–55. doi:10.1017/S0264180100000412. PMID 2908516.

[13] Authier, N.; Balayssac, D.; Sautereau, M.; Zangarelli, A.; Courty, P.; Somogyi, AA.; Vennat, B.; Llorca, PM.; Eschalier, A. (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr. 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.

[14] Joyce JR, Bal TS, Ardrey RE, Stevens HM, Moffat AC (June 1984). "The decomposition of benzodiazepines during analysis by capillary gas chromatography/mass spectrometry". Biomed Mass Spectrom. 11 (6): 284–9. doi:10.1002/bms.1200110607. PMID 6743768.

[15] Food and Drug Administration (January 2006). "FDA Public Health Advisory - Consumers Filling U.S. Prescriptions Abroad May Get the Wrong Active Ingredient Because of Confusing Drug Names". FDA (USA). Archived from the original on 12 August 2006. Retrieved 26 August 2006.

[16] Drug Enforcement Administration (USA). "Drug Scheduling". United States Government. Retrieved 26 August 2008.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

Clinical data


AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	?
Routes of administration	Oral
ATC code	N05BA10 (WHO)
Legal status
Legal status	Schedule IV(US)
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Elimination half-life	26-200 hours
Excretion	Renal
Identifiers
IUPAC name 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl-4H-[1,3]oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione^[1]
CAS Number	27223-35-4^Y
PubChem CID	33746
DrugBank	DB01587^Y
ChemSpider	31110^Y
UNII	92A214MD7Y
KEGG	D04650^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₀H₁₇ClN₂O₃
Molar mass	368.8
3D model (JSmol)	Interactive image
SMILES ClC1=CC2=C(N(C)C(CN3C(C=C(C)OC32C4=CC=CC=C4)=O)=O)C=C1
InChI InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3^Y Key:PWAJCNITSBZRBL-UHFFFAOYSA-N^Y
(verify)